OWD
VRTX icon

Osborn Williams & Donohoe’s Vertex Pharmaceuticals VRTX Stock Holding History

Osborn Williams & Donohoe’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,100
Closed -$202K – 323
2019
Q2 		$202K Buy
1,100
+600
+120% +$105K 0.02% 309
2019
Q1 		$93K Buy
+500
New +$92.4K 0.01% 420

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Osborn Williams & Donohoe's VRTX Position: Q3 2019 in Review

Osborn Williams & Donohoe sold out of Vertex Pharmaceuticals (VRTX) in Q3 2019, closing a stake of 1,100 shares — an estimated $202K sold.

Osborn Williams & Donohoe first reported a position in VRTX in Q1 2019 and held it in 2 quarters. The position peaked at $202K in Q2 2019. 708 funds tracked by Wall St. Rank hold VRTX as of Q3 2019.

  • Osborn Williams & Donohoe reported no remaining Vertex Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Osborn Williams & Donohoe sold 1,100 Vertex Pharmaceuticals shares in Q3 2019, an estimated $202K.
  • Osborn Williams & Donohoe first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Osborn Williams & Donohoe's Vertex Pharmaceuticals position peaked at $202K in Q2 2019.
  • 708 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q3 2019, filed 16 Oct 2019.